Table 3.

The distribution of abdominal fat measured by CT scan among BE cases, colonoscopy control group and endoscopy control groups all stratified by the absence or presence of GERD symptoms or PPI use

GERD and PPI negative patients	BE Cases (n=31) %	Colonoscopy controls (n=219) %	Unadjusted OR	Adjusted* OR	Endoscopy controls (n=41) %	Unadjusted OR	Adjusted* OR
VAT
Below median	13 (42)	122 (56)	1.00	1.00	29 (71)	1.00	1.00
Median and above	18 (58)	97 (44)	1.74 (0.81–3.73)	1.24 (0.56–2.75)	12 (29)	3.35 (1.26–8.92)	2.30 (0.79–6.72)
p Trend		0.16			0.01
VAT/SAT ratio
Below median	12 (39)	121 (55)	1.00	1.00	23 (56)	1.00	1.00
Median and above	19 (61)	98 (45)	1.96 (0.91–4.22)	1.35 (0.61–3.03)	18 (44)	2.02 (0.78–5.23)	1.15 (0.36–3.53)
p Trend		0.09			0.14

GERD or PPI positive patients	BE Cases (n=136) %	Colonoscopy controls (n=115) %	Unadjusted OR	Adjusted* OR	Endoscopy controls (n=127) %	Unadjusted OR	Adjusted* OR
VAT
Below median	49 (36)	62 (54)	1.00	1.00	60 (47)	1.00	1.00
Median and above	87 (64)	53 (46)	2.08 (1.25–3.45)	1.68 (0.98–2.88)	67 (53)	1.59 (0.97–2.61)	1.28 (0.75–2.18)
p Trend		<0.01			0.06
VAT/SAT ratio
Below median	57 (42)	59 (51)	1.00	1.00	56 (44)	1.00	1.00
Median and above	79 (58)	56 (49)	1.46 (0.89–2.41)	1.00 (0.57–1.74)	71 (56)	1.09 (0.67–1.78)	0.67 (0.39–1.78)
p Trend		0.22			0.72

^*Adjusted for age, gender, NSAID, Helicobacter pylori infection, smoking and alcohol.

BE, Barrett’s oesophagus; PPI, propton pump inhibitors; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.